Minor Skin Disorders without MCC DRG Reimbursement Guide

DRG 607 groups inpatient stays for minor skin and subcutaneous tissue disorders without Major Complication or Comorbidity, encompassing uncomplicated infections, minor excisions, and simple wound procedures. It matters for inpatient reimbursement because the Diagnosis-Related Group assignment establishes the Medicare payment bundle tied to expected resource use for these less complex skin conditions.

DRG 607 Overview

DRG 607 covers admissions for minor skin and subcutaneous tissue disorders without Major Complication or Comorbidity and typically includes conditions such as localized infections, simple skin grafts, and benign skin lesions requiring inpatient care. This Diagnosis-Related Group is relevant for Medicare payment because it defines a bundled payment rate based on the expected resource use for uncomplicated skin conditions. Hospitals use the DRG assignment to determine reimbursement under the inpatient prospective payment system. Accurate coding and documentation of comorbidities and procedures affect whether an admission qualifies for this DRG.

Acute wound-care and infection management trials: studies testing different topical antiseptics, short-course systemic antibiotics, or wound dressings for commonly hospitalized minor skin conditions (such as cellulitis limited to superficial tissues, infected ulcers without systemic signs, or acute contact dermatitis needing inpatient analgesia). These trials enroll adult or pediatric inpatients with minor skin disorders presenting for short-stay care and focus on rapid resolution of local inflammation, prevention of progression to deeper infection, and reductions in length of stay. Results are directly relevant to clinicians aiming to standardize initial inpatient treatment pathways and to payers seeking evidence to support cost-effective first-line regimens that minimize inpatient resource use and readmissions.
Comparative effectiveness studies of diagnostic and triage strategies: pragmatic trials or cohort studies comparing approaches such as bedside ultrasound assessment, dermatology consultation versus emergency physician management, or use of validated diagnostic algorithms for differentiating cellulitis from mimics (e.g., stasis dermatitis, eczema, or lipodermatosclerosis). These studies enroll patients admitted or evaluated for minor skin disorders whose diagnoses are uncertain and measure outcomes like diagnostic accuracy, time to appropriate therapy, inpatient length of stay, and downstream testing. Findings help hospitals and payers optimize triage, reduce unnecessary admissions and imaging, and allocate specialty consultation resources more efficiently.
Post-discharge outcomes and care-transition research: observational cohorts or randomized trials evaluating follow-up strategies (early outpatient dermatology or wound clinic visits, telehealth monitoring, or home nursing support) to prevent recurrence, monitor healing, and avoid readmission for patients discharged after treatment for minor skin conditions. These studies focus on patients discharged after short inpatient stays or observation, measuring rates of treatment failure, emergency revisits, patient-reported outcomes, and total 30- to 90-day costs of care. Evidence from this research informs discharge planning protocols and payer policies on coverage for post-discharge services that can reduce readmissions and overall expenditures.

Acute wound-care and infection management trials: studies testing different topical antiseptics, short-course systemic antibiotics, or wound dressings for commonly hospitalized minor skin conditions (such as cellulitis limited to superficial tissues, infected ulcers without systemic signs, or acute contact dermatitis needing inpatient analgesia). These trials enroll adult or pediatric inpatients with minor skin disorders presenting for short-stay care and focus on rapid resolution of local inflammation, prevention of progression to deeper infection, and reductions in length of stay. Results are directly relevant to clinicians aiming to standardize initial inpatient treatment pathways and to payers seeking evidence to support cost-effective first-line regimens that minimize inpatient resource use and readmissions.
Comparative effectiveness studies of diagnostic and triage strategies: pragmatic trials or cohort studies comparing approaches such as bedside ultrasound assessment, dermatology consultation versus emergency physician management, or use of validated diagnostic algorithms for differentiating cellulitis from mimics (e.g., stasis dermatitis, eczema, or lipodermatosclerosis). These studies enroll patients admitted or evaluated for minor skin disorders whose diagnoses are uncertain and measure outcomes like diagnostic accuracy, time to appropriate therapy, inpatient length of stay, and downstream testing. Findings help hospitals and payers optimize triage, reduce unnecessary admissions and imaging, and allocate specialty consultation resources more efficiently.
Post-discharge outcomes and care-transition research: observational cohorts or randomized trials evaluating follow-up strategies (early outpatient dermatology or wound clinic visits, telehealth monitoring, or home nursing support) to prevent recurrence, monitor healing, and avoid readmission for patients discharged after treatment for minor skin conditions. These studies focus on patients discharged after short inpatient stays or observation, measuring rates of treatment failure, emergency revisits, patient-reported outcomes, and total 30- to 90-day costs of care. Evidence from this research informs discharge planning protocols and payer policies on coverage for post-discharge services that can reduce readmissions and overall expenditures.

OpenPayer

Summary & Overview

Minor Skin Disorders without MCC: Inpatient Reimbursement Overview

DRG 607 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes